PRESS RELEASE 2008

• FDA Approves Ferring Pharmaceuticals’ Degarelix (Generic Name) for Treatment of Advanced Prostate Cancer

Ferring Pharmaceuticals, USA today received approval from the U.S. Food and Drug Administration (FDA) for degarelix…

• Committee for Medicinal Products for Human Use (CHMP) recommends granting marketing authorisation for FIRMAGON® (degarelix) for treatment of prostate cancer

Ferring Pharmaceuticals received today notification that the Committee…

• Ferring and Conaris complete license agreement for new recombinant molecule in gastroenterology

Ferring Pharmaceuticals and Conaris Research Institute AG today announced that they have completed…

• Ferring signs distribution agreement with BioGaia in Ireland and the Middle East

BioGaia has extended its collaboration with the Swiss biopharmaceutical company Ferring Pharmaceuticals giving Ferring exclusive rights to sell BioGaia’s Probiotic Drops in Ireland and…

• Auxilium Pharmaceuticals, Inc. Announces Distribution and License Agreement for Testim® in Europe with Ferring Pharmaceuticals

Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) and Ferring International S.A. today announced…

• Positive phase III data unveiled for new GnRH blocker degarelix

Data from a Phase III study presented at the 23rd Annual European Association of Urology Congress demonstrated that the investigational GnRH blocker, degarelix…

• Ferring Pharmaceuticals submits new drug application for degarelix, a prostate cancer treatment

Ferring Pharmaceuticals announced today that it has submitted applications in Europe and the United States for…

• Launch of new, prestigious infertility and gynaecology research grant (FRIGGA) at “Update in Infertility 2008”

Ferring Pharmaceuticals today launches the first Ferring Research Infertility and Gynaecology GrAnt (FRIGGA) for fundamental fertility and gynaecology research…